-       Report 
   - July 2022
    -  165 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                -       Report 
   - February 2024
    -  75 Pages 
    Global
   
   From       €4442EUR$4,950USD£3,898GBP 
                -       Report 
   - October 2022
    -  68 Pages 
    Global
   
             -       Report 
   - November 2021
    -  106 Pages 
    Global
   
   From       €4442EUR$4,950USD£3,898GBP 
                -       Report 
   - February 2023
    -  200 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                 -       Report 
   - October 2021
    -  210 Pages 
    Global
   
   From       €3365EUR$3,750USD£2,953GBP 
                -       Report 
   - April 2023
    -  501 Pages 
    Global
   
   From       €4487EUR$5,000USD£3,938GBP 
                -       Report 
   - April 2023
    -  200 Pages 
    Global
   
   From       €4487EUR$5,000USD£3,938GBP 
                -       Report 
   - February 2023
    -  175 Pages 
    Global
   
   From       €4487EUR$5,000USD£3,938GBP 
                -       Report 
   - April 2024
    -  183 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                -       Report 
   - March 2024
    -  200 Pages 
    Global
   
   From       €3724EUR$4,150USD£3,268GBP 
                -       Report 
   - January 2024
    -  200 Pages 
    Global
   
   From       €3724EUR$4,150USD£3,268GBP 
                  -       Report 
   - July 2024
    -  100 Pages 
    Global
   
   From       €2692EUR$3,000USD£2,363GBP 
      €3365EUR$3,750USD£2,953GBP 
                  -       Report 
   - July 2024
    -  100 Pages 
    Global
   
   From       €2692EUR$3,000USD£2,363GBP 
      €3365EUR$3,750USD£2,953GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                  -       Report 
   - April 2023
    -  500 Pages 
    Global
   
   From       €2333EUR$2,600USD£2,048GBP 
      €2916EUR$3,250USD£2,560GBP 
                  -       Report 
   - April 2023
    -  200 Pages 
    Global
   
   From       €2836EUR$3,160USD£2,489GBP 
      €3544EUR$3,950USD£3,111GBP 
                  -       Report 
   - January 2022
    -  60 Pages 
    Global
   
   From       €2836EUR$3,160USD£2,489GBP 
      €3544EUR$3,950USD£3,111GBP 
                -       Report 
   - July 2024
    -  110 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
             
         Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer.
Car T therapies are a    relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer.
Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less   Read more